Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P35658

UPID:
NU214_HUMAN

ALTERNATIVE NAMES:
214 kDa nucleoporin; Nucleoporin Nup214; Protein CAN

ALTERNATIVE UPACC:
P35658; A6NFQ0; Q15010; Q3KQZ0; Q5JUP7; Q75R47; Q86XD3

BACKGROUND:
The protein Nup214, known alternatively as 214 kDa nucleoporin or Protein CAN, is integral to the nuclear pore complex's function. It facilitates nucleocytoplasmic transport and serves as a critical docking site for the import of substrates. Nup214 also plays a role in the disassembly of the human adenovirus 5 capsid, allowing the viral genome to enter the nucleus.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Nuclear pore complex protein Nup214 could open doors to potential therapeutic strategies. Its involvement in Encephalopathy, acute, infection-induced, 9, a disorder characterized by neurodevelopmental regression, positions Nup214 as a key target in the development of novel treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.